20:49 , May 24, 2019 |  BioCentury  |  Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

It is clear that Europe has hotspots of innovation that are discovering and developing the next wave of new therapeutic modalities. Nearly every category of new modality has a European champion, with clusters forming around...
21:15 , May 18, 2018 |  BioCentury  |  Finance

China comes to Europe

  The historically underfunded European biotech sector is in the early stages of tapping into a new stream of capital thanks to the explosion of biomedical innovation in China, which has spawned a wave of...
22:53 , May 26, 2017 |  BioCentury  |  Finance

Europe’s bellwether challenge

A healthy biotech ecosystem comprises a continuum from big pharma and bellwether biotechs at the top to private newcos at the bottom, with a mixture of liquidity events -- predominantly M&A -- to reward investors....
08:00 , Jan 18, 2016 |  BC Week In Review  |  Financial News

Cardiorentis completes venture financing

Cardiorentis AG , Zug, Switzerland   Business: Cardiovascular   Date completed: 2016-01-11   Type: Venture financing   Raised: CHF60 million ($60.1 million)   Investor: High net worth investors  ...
02:45 , Jan 12, 2016 |  BC Extra  |  Financial News

Cardiorentis raises CHF60M in series B

Cardiorentis AG (Zug, Switzerland) raised CHF60 million ($60.1 million) in a series B round. Spokesperson Kellie Walsh May said three "ultra-high net worth European investors" participated, but declined to name them. The company expects results...
07:00 , Jun 1, 2015 |  BC Week In Review  |  Clinical News

Ularitide: Completed Phase III enrollment

Cardiorentis completed enrollment of 2,157 patients in the double-blind, placebo-controlled, international Phase III TRUE-AHF trial evaluating 15 ng/kg IV ularitide given over 48 hours plus standard of care, which may include vasodilator, inotropic and diuretic...
07:00 , May 25, 2015 |  BioCentury  |  Finance

Innovation underfed

Stephen Hansen, Associate Editor   Europe's Iceberg 2015 Despite world-class research institutions and a crop of novel drugs making their way through the clinic, European biotech is finding it hard to reach the end zone...
08:00 , Nov 3, 2014 |  BC Week In Review  |  Company News

Cardiorentis, Roche deal

Cardiorentis will incorporate undisclosed in vitro diagnostics from Roche in the ongoing Phase III TRUE-AHF trial to characterize the therapeutic benefits of Cardiorentis' ularitide in acute decompensated heart failure (ADHF). Cardiorentis said it plans to...
07:00 , Sep 22, 2014 |  BC Week In Review  |  Financial News

Cardiorentis completes venture financing

Cardiorentis AG , Zug, Switzerland   Business: Cardiovascular   Date completed: 2014-09-17   Type: Venture financing   Raised: EUR45 million ($58.2 million)   Investor: Healthcare Royalty Partners  ...
07:00 , May 5, 2014 |  BC Week In Review  |  Company News

Moleac board of directors update

Moleac Pte. Ltd. , Singapore   Business: Neurology   Appointed: Elmar Schnee as non-executive chairman, formerly CEO of Cardiorentis AG ; he succeeds Marc Vasseur  ...